title: Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma.
abstract: A 13-year-old boy with chemotherapy-resistant diffuse large B-cell lymphoma (DLBCL) was successfully treated with autologous peripheral blood stem cell transplantation (auto-PBSCT) with administration of rituximab. Previous reports indicate that auto-PBSCT without rituximab for adult chemotherapy-resistant DLBCL is only marginally successful. The addition of rituximab administration might have intensified anti-tumor activity before the transplant procedure and might have enhanced the in vivo purging of the auto-graft, resulting in a successful outcome in this case. Although a few adverse effects are linked to rituximab administration, such as prolonged neutropenia, hypogammaglobulinemia, and increased infectious complications, the regimen of rituximab with SCT appears to be effective against chemotherapy-resistant DLBCL.
authors.affiliation: Department of Pediatrics, Matushita Memorial Hospital, Moriguchi, Japan. imamura@koto.kpu-m.ac.jp
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Imamura
authors.forename: Takao
authors.initials: T
authors.lastname: Yoshihara
authors.forename: Akira
authors.initials: A
authors.lastname: Morimoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ishida
authors.forename: Tohru
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Shinsaku
authors.initials: S
authors.lastname: Imashuku
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018572:Disease-Free Survival; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012074:Remission Induction; D000069283:Rituximab; D013160:Splenic Neoplasms / Q000473:pathology / Q000628:therapy; D014182:Transplantation, Autologous
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab